ATE278414T1 - Therapien zur behandlung von akutem nierenversagen - Google Patents
Therapien zur behandlung von akutem nierenversagenInfo
- Publication number
- ATE278414T1 ATE278414T1 AT98919715T AT98919715T ATE278414T1 AT E278414 T1 ATE278414 T1 AT E278414T1 AT 98919715 T AT98919715 T AT 98919715T AT 98919715 T AT98919715 T AT 98919715T AT E278414 T1 ATE278414 T1 AT E278414T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- therapies
- kidney failure
- acute kidney
- risk
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
- 208000033626 Renal failure acute Diseases 0.000 title abstract 2
- 201000011040 acute kidney failure Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4561997P | 1997-05-05 | 1997-05-05 | |
| PCT/US1998/003197 WO1998050060A1 (en) | 1997-05-05 | 1998-05-05 | Therapies for acute renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE278414T1 true ATE278414T1 (de) | 2004-10-15 |
Family
ID=21938961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98919715T ATE278414T1 (de) | 1997-05-05 | 1998-05-05 | Therapien zur behandlung von akutem nierenversagen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100105621A1 (https=) |
| EP (1) | EP0980252B1 (https=) |
| JP (2) | JP5033276B2 (https=) |
| AT (1) | ATE278414T1 (https=) |
| AU (1) | AU743510B2 (https=) |
| CA (1) | CA2289123A1 (https=) |
| DE (1) | DE69826854T2 (https=) |
| DK (1) | DK0980252T3 (https=) |
| ES (1) | ES2226125T3 (https=) |
| PT (1) | PT980252E (https=) |
| WO (1) | WO1998050060A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60143078D1 (de) * | 2000-01-31 | 2010-10-28 | Uwe Waldemar Rothenpieler | Pax2 zur behandlung von nierenkrankheiten |
| US7612046B2 (en) | 2000-01-31 | 2009-11-03 | Uwe Waldemar Rothenpieler | Method for treating kidney disorders |
| EP1407770B1 (en) | 2001-06-26 | 2013-06-05 | Takeda Pharmaceutical Company Limited | Tgf-beta superfamily production/secretion promoter |
| US20050272649A1 (en) * | 2002-08-28 | 2005-12-08 | Hruska Keith A | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
| RU2282899C2 (ru) * | 2004-01-09 | 2006-08-27 | ГОУ ВПО Омская Государственная Медицинская Академия | Способ моделирования инфекции мочевой системы |
| EP3147296A1 (en) * | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
| WO2008010556A1 (fr) * | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
| US8979797B2 (en) * | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| WO2015119253A1 (ja) | 2014-02-07 | 2015-08-13 | 宮崎 徹 | 腎疾患の予防または治療剤 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) * | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5045452A (en) * | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| DK0429570T3 (da) | 1989-03-28 | 1998-04-27 | Genetics Inst | Osteoinducerende præparater |
| WO1991018098A1 (en) | 1990-05-16 | 1991-11-28 | Genetics Institute, Inc. | Bone and cartilage inductive proteins |
| JPH0426624A (ja) | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| JPH05509086A (ja) | 1990-06-22 | 1993-12-16 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療 |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| DK0575555T3 (da) | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US7056882B2 (en) * | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| EP0825442A3 (en) | 1991-08-30 | 2004-02-11 | Curis, Inc. | Morphogenic protein screening method |
| JP3693338B2 (ja) * | 1991-08-30 | 2005-09-07 | キュリス インコーポレイテッド | 組織形成因子誘導による炎症反応の調節 |
| DE69233559T2 (de) * | 1991-08-30 | 2006-08-31 | Curis, Inc., Cambridge | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| CA2141556A1 (en) | 1992-07-31 | 1994-02-17 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| DE69333745T2 (de) | 1992-07-31 | 2005-12-29 | Stryker Corp., Kalamazoo | Löslicher komplex morphogener proteine und zusammensetzungen davon |
| PT653942E (pt) * | 1992-07-31 | 2003-11-28 | Curis Inc | Regeneracao e reparacao de nervos induzidos por morfogenios |
| CA2144514C (en) | 1992-09-16 | 2002-03-26 | Thangavel Kuberasampath | Morphogen-induced liver regeneration |
| CA2147598A1 (en) | 1992-11-03 | 1994-05-11 | Stryker Corporation | Op-3-induced morphogenesis |
| JPH08510446A (ja) | 1993-03-04 | 1996-11-05 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 組換え骨形成タンパク質を生成するための方法および組成物 |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| CA2176709A1 (en) * | 1993-11-15 | 1995-05-26 | Howard R. Higley | Method of treating renal disease by administering igf-i and igfbp-3 |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| EP0894004B2 (en) * | 1996-03-22 | 2007-02-21 | Curis, Inc. | Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma |
| US5820589A (en) * | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1998
- 1998-05-05 CA CA002289123A patent/CA2289123A1/en not_active Abandoned
- 1998-05-05 ES ES98919715T patent/ES2226125T3/es not_active Expired - Lifetime
- 1998-05-05 AU AU72443/98A patent/AU743510B2/en not_active Ceased
- 1998-05-05 DE DE69826854T patent/DE69826854T2/de not_active Expired - Lifetime
- 1998-05-05 AT AT98919715T patent/ATE278414T1/de active
- 1998-05-05 WO PCT/US1998/003197 patent/WO1998050060A1/en not_active Ceased
- 1998-05-05 JP JP54804898A patent/JP5033276B2/ja not_active Expired - Fee Related
- 1998-05-05 EP EP98919715A patent/EP0980252B1/en not_active Expired - Lifetime
- 1998-05-05 PT PT98919715T patent/PT980252E/pt unknown
- 1998-05-05 DK DK98919715T patent/DK0980252T3/da active
-
2009
- 2009-08-11 US US12/583,013 patent/US20100105621A1/en not_active Abandoned
- 2009-09-11 JP JP2009211128A patent/JP2009286802A/ja not_active Withdrawn
-
2011
- 2011-04-04 US US13/079,161 patent/US8748378B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110257093A1 (en) | 2011-10-20 |
| US8748378B2 (en) | 2014-06-10 |
| DE69826854T2 (de) | 2006-02-02 |
| DE69826854D1 (de) | 2004-11-11 |
| PT980252E (pt) | 2005-01-31 |
| AU7244398A (en) | 1998-11-27 |
| AU743510B2 (en) | 2002-01-24 |
| ES2226125T3 (es) | 2005-03-16 |
| WO1998050060A1 (en) | 1998-11-12 |
| JP5033276B2 (ja) | 2012-09-26 |
| DK0980252T3 (da) | 2005-01-31 |
| JP2009286802A (ja) | 2009-12-10 |
| EP0980252B1 (en) | 2004-10-06 |
| JP2001523264A (ja) | 2001-11-20 |
| EP0980252A1 (en) | 2000-02-23 |
| CA2289123A1 (en) | 1998-11-12 |
| US20100105621A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69730966D1 (de) | Morphogenische behandlung des chronischen nierenversagens | |
| ATE278414T1 (de) | Therapien zur behandlung von akutem nierenversagen | |
| EA199801044A1 (ru) | Модуляторы регенерации тканей | |
| DK0429570T3 (da) | Osteoinducerende præparater | |
| DE69736974D1 (de) | System zur filtration von medizinischen und biologischen flüssigkeiten | |
| DE69827192D1 (de) | Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen | |
| EA200000445A1 (ru) | Способы лечения состояния гиперкоагуляции или приобретенной недостаточности белка c | |
| DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
| DK52089D0 (da) | Middel til behandling af nyresygdomme | |
| ATE273031T1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| DE69633393D1 (de) | Mitteln zur behandlung von auto-immun krankheiten | |
| EP0960117A4 (en) | ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| TR199900596T2 (xx) | Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�. | |
| ATA113492A (de) | Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven | |
| DE69721484D1 (de) | Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten | |
| IT1292798B1 (it) | Sistema sterile e procedimento di filtraggio di liquidi biologici o medicali, in particolare di sangue o componenti del sangue. | |
| FI952170L (fi) | Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi | |
| NO945031D0 (no) | Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner | |
| DE69829995D1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE59805246D1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
| FR2764389B1 (fr) | Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee | |
| Liu et al. | Cell saver filtering of extravasated rhBMP-2 after degenerative scoliosis reconstruction | |
| ATA159597A (de) | Präparat zur behandlung von blutgerinnungsstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0980252 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |